Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals, Inc., filed a Form 4 on November 2, 2026, disclosing the acquisition of 100,000 restricted stock units on October 30, 2026.

Key Highlights

  • Grant date: Bhatt acquired 100,000 restricted stock units (RSUs) on October 30, 2026, at a price of $0.
  • Vesting structure: 50% of RSUs vest upon the closing of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc.
  • Subsequent installments: 15% vest on the one-year anniversary of the closing, 15% on the two-year anniversary, and 20% on the three-year anniversary.
  • Settlement: RSUs are settled in common stock upon vesting, according to the filing.
  • Resulting ownership: Bhatt beneficially owns 100,000 derivative securities following the reported transaction, held directly.
  • Role: Bhatt is identified in the filing as an officer with the title "Sr. VP of IP, CSO."

Supernus CSO Bhatt Awarded Merger-Contingent RSUs on October 30, 2026

According to the Form 4 filed with the SEC on November 2, 2026, Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), received an award of 100,000 restricted stock units on October 30, 2026. The filing records the transaction code as "A" (acquisition) under Table II covering derivative securities, with the price of the derivative security listed as $0.

The filing explains that the RSUs are settled in common stock upon vesting and are subject to a four-installment schedule. As disclosed, 50% of the RSUs vest upon the closing of the "merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc." The remaining RSUs vest in three subsequent installments: 15% on the one-year anniversary of the closing, 15% on the two-year anniversary, and 20% on the three-year anniversary of the closing. The underlying security for all 100,000 RSUs is common stock.

Following the reported transaction, the filing states that Bhatt beneficially owns 100,000 derivative securities directly. The Form 4 was signed by Timothy C. Dec as attorney-in-fact on November 2, 2026. No transactions were reported in Table I covering non-derivative securities.

What Was Disclosed

The filing discloses a grant of 100,000 RSUs to Supernus officer Padmanabh P. Bhatt on October 30, 2026, with vesting contingent on the closing of the Supernus-Indivior merger and subsequent anniversaries thereof.